Covalently bound conjugates of albumin and heparin: Synthesis, fractionation and characterization by Hennink, Wim E. et al.
THROMBOSIS RESEARCH 29; 1-13, 1983 
0049-3848/83/010001-13$03.00/O Printed in the USA. 
Copyright (c) 1983 Pergamon Press Ltd. All rights reserved. 
COVALENTLV BOUND CONJUGATES OF ALBUMIN AND HEPARIN: 
SYNTHESIS, FRACTIONATION AND CHARACTERIZATION 
Wim E. Hennink, Jan Feijen, Charles D. Ebert* and Sung Wan Kim* 
Department of Chemical Technology, Biomaterials Section 
Twente University of Technology, P.O. Box 217, Enschede, The Netherlands 
*Department of Pharmaceutics, University of Utah 
Salt Lake City, Utah 84112, U.S.A. 
(Received 14.4.1982; in revised form 22.9.1982. 
Accepted by Editor C.R.M. Prentice) 
ABSTRACT 
Covalently bound conjugates of human serum albumin and heparin were 
prepared as compounds which could improve the blood-compatibility 
of polymer surfaces either by preadsorption or by covalent coupling 
ofthe conjugates onto blood contacting surfaces. The conjugates 
(lo-16 weight % of heparin) were obtained by a condensation reaction 
between albumin and heparin using 1-ethyl-3-(dimethylaminopropyl)- 
carbodiimide. Unreacted albumin and heparin were removed bydiethyl- 
aminoethyl (DEAE)-cellulose and Cibacron Blue Sepharose chromato- 
graphy respectively. The activity of the heparin component incorpo- 
rated in the albumin-heparin conjugates (AC) was compared with that 
of the heparin used for the synthesis of the conjugates (Anat) by 
thrombin time, inhibition of Factor Xa and the activated partial 
thromboplastin time (APTT) assays. The Ac/Anat ratio for the above 
assays was as follows: Thrombin time 1.25, Factor Xa inhibition 
0.5. and APTT 0.5. Gel filtration chromatography showed broad- 
molecular weight distributions. The conjugates were fractionated 
using immobilized antithrombin III (ATIII). High AT111 and low 
AT111 affinity conjugate fractions showed the same behavior as AT111 
fractionated heparin with respect to thrombin times and Factor Xa 
inhibition. 
INTRODUCTION 
Much effort has been made to improve the blood compatibility of materials 
by treatment of surfaces using either heparin or human serum albumin. Human 
serum albumin reduces both the adhesion of blood platelets and the activation 
Keywords: albumin-heparin conjugates, heparin, anticoagulant activity, 
antithrombin III. 
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of the intrinsic blood coagulation (for reviews, see 1, 2, 3). Heparin has 
been covalently or ionically bound to material surfaces. In general, surfaces 
prepared by the first method are less blood compatible than those prepared by 
the latter method, where leakage of heparin from the surface might play an 
important role. Alternatively, controlled release of heparin from material 
surfaces might also be a good approach to improve blood compatibility (4). 
Albumin-heparin conjugates might be useful to obtain material surfaces 
with improved blood compatibility either by the adsorption of the conjugate 
on hydrophobic materials through the albumin moiety or by covalent coupling 
of the conjugate to surfaces using albumin as a spacer. Presumably after 
contact with blood, the preadsorbed surfaces will show a gradual desorption 
of the conjugate, thus preventing thrombosis at the surface. 
In this paper we describe the synthesis, fractionation and characteriza- 
tion of albumin-heparin conjugates, which will later be investigated as possi- 
ble compounds for the improvement of the blood compatibility of polymeric 
surfaces. 
MATERIALS AND METHODS 
Reagents 
Heparin from porcine mucosa was obtained from Diosynth, Oss, The Nether- 
lands. The specific activity as indicated by the manufacturer was 161.5 IU/ 
mg. Human serum albumin (No.A9511) was obtained from Sigma, St. Louis, USA 
and was used without further purification, Cibacron Blue Sepharose CL-6B, 
CNBr-activated Sepharose and Sephacryl S-300 were all purchased from Pharmacia 
Fine Chemicals, Uppsala, Sweden. Purified human antithrombin III was a gener- 
ous gift of the American Red Cross. 1-ethyl-3-(dimethylaminopropyl)-carbodi- 
imide (EDC) and N-ethyl-5-phenylisoxazolium-3'-sulfonate (Woodward's reagent 
K) were products of Aldrich, Beerse, Belgium. Coatest Heparin was obtained 
from Kabi Vitrum, Stockholm, Sweden. PTT-reagent was ObtainedfromBoehringer, 
Mannheim, F.R.G. Thrombin (75 NIH U/mg) was obtained from Hoffman La Roche, 
Switzerland. CPD human plasma was obtained from the Red Cross Bloodbank 
Groningen-Drenthe, Groningen, The Netherlands. 
Synthesis and Fractionation of Conjugates 
In a typical experiment, heparin (770 mg)and albumin (2590 mg) were 
dissolved in water (39 ml) and this solution was adjusted to pH 5.1-5.2 with 
HCl (1N). During the addition of 1 N HCl, a white precipitate was formed, 
which contained both heparin and albumin (5). The precipitate dissolved 
almost completely within 1 hour. Eight 1 ml portions of EDC (c = 32.5 mg/ml) 
solution were added to the resulting solution at 30 minute intervals. The pH 
was maintained at 5.1-5.2 by the addition of HCl (1 N) or NaOH (1N). Thirty 
minutes after the last addition of EDC, the pH was adjusted to pH 7.5 with 
NaOH (1 N) and the solution was gently stirred for 20 hours. Finally the 
solution was dialyzed for 2 hours against 0.025 M Tris-HCl, pH 7.5. The total 
experiment was performed at room temperature. 
Separation of the albumin-heparin conjugate from free albumin and heparin 
was achieved by the following chromatographic procedures. The dialyzed 
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solution containing the conjugate was applied to a column of DEAE-cellulose 
(Whatman DE 32) which was previously equilibrated with 0.025 M Tris-HCl, pH 
7.5. In order to remove unbound material, the column was washed with 1 column 
volume of 0.025 M Tris-HCl, pH 7.5. It was shown that 5-10 mg of reactants 
and products could be bound per ml packed gel. Free albumin was eluted with 
approximately 2 column volumes of 0.15 M NaCl-0.025 M Tris-HCl, pH 7.5. This 
eluate was discarded. To elute both the albumin-heparin conjugate as well as 
free heparin, a 0.50 M NaCl-0.025 M Tris-HCl, pH 7.5, buffer solution was 
used. Fractions with an optical density exceeding 0.2 at 280 nm were pooled 
and used for further purification with a'cibacron Blue Sepharose column. This 
material binds albumin and the interaction can be broken with potassium thio- 
cyanate (KSCN) (6,7). The pooled fractions obtained with the DEAE-cellulose 
column were applied to a column of Cibacron Blue Sepharose (binding capacity 
ca 15 mg conjugate per ml packed gel). This column was equilibrated with 0.17 
M NaCl-0.025 M Tris-HCl, pH 7.5. Free heparin was removed by eluting the 
column with 1 column volume of 0.17 M NaCl-0.025 M Tris-HCl, pH 7.5, buffer. 
Then the albumin-heparin conjugate was eluted with 0.17 M NaCl-0.25 M KSCN- 
0.025 M Tris-HCl, pH 7.5. Fractions with an optical density exceeding 0.2 at 
280 nm were pooled and extensively dialyzed against water. The conjugate was 
collected by freeze drying and the product was stored at 4OC. This product 
was used for further studies. All chromatographic procedures were performed 
at 4OC. 
Determination of Heparin Concentrations 
Heparin concentrations of the different column eluates were routinely 
determined according to a slightly modified metachromic assay described by 
Jacques et al. (8). To a solution of Azure A (3 ml, OD 505 nm f 0.8) in bar- 
bital buffer (pH 8.6, ionic strength 0.04) an aqueous solution of heparin 
(5-100 ~1, maximal concentration 5 mg/ml) was added. After mixing, the 
adsorption at 505 nm was measured against a similar solution of Azure A con- 
taining no heparin. The weight percentage of heparin in the albumin-heparin 
conjugates obtained after freeze drying was determined by 2 independent 
methods, the metachromic assay described above and the uranic acid assay 
described by Blumenkranz (9). 
Determination of Albumin Concentrations 
The albumin concentrations of the different column eluates were deter- 
mined spectrophotometrically (10). The weight percentages of albumin in the 
albumin-heparin conjugates obtained were determined by the same method. 
Biological Assays of the Albumin-Heparin Conjugate 
Thrombin times of titrated plasma were performed with a Mechrolab Clot- 
timer (Heller Laboratories, Santa Rosa, U.S.A.). A solution of heparin or 
albumin-heparin conjugate dissolved in saline (50 ~1) was added to the plasma 
(950 Vl). After 5 minutes incubation at 37"C, the plasma solution (100 ~1) 
was added to a thrombin solution (200 ~1, 3.0 NIH U) at 37OC and clotting 
times were registered. 
Activated parital thromboplastin time (APTT) was also determined with a 
Mechrolab Clottimer. A solution of heparin or albumin-heparin conjugate in 
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saline (50 ~1) was added to plasma (950 ~1). After 5 minutes incubation at 
37oC, the plasma solution (100 ~1) was mixed with a suspension of Kaolin and 
Cephalin (PTT-reagent from Boehringer, 100 ~1). After an incubation time of 
exactly 3 minutes, CaC12 (100 Pl, 0.025 M) was added and the clotting time 
was registered. 
Anti-Factor Xa activity of heparin and the albumin-heparin conjugate was 
determined according to the method described by Teien (11). 
Gel Filtration Stud,yofthe Conjugate of Albumin and Heparin 
Albumin-heparin conjugate (75 mg) was dissolved in 5 ml 0.17 M NaCl- 
0.025 M Tris-HCl, pH 7.5. This solution was applied to a column (2.6 cm x 95 
cm) of Sephacryl S-300, which was equilibrated with 0.17 M NaCl-0.025 M Tris- 
HCl, pH 7.5. Elution was performed with the same buffer at a flow rate of 20 
ml/hr and 4.5 ml fractions were collected. A solution of albumin (60 mg) and 
heparin (15 mg) in 5 ml 0.17 M NaCl-0.025 M Tris-HCl, pH 7.5, was eluted in 
the same way. 
Fractionation of the Albumin-Heparin Conjugate with Immobilized Antithrombin 
III 
Purified antithrombin III was coupled via amino groups to CNBr-activated 
Sepharose in the presence of heparin (12). Antithrombin III (46 mg) as 
received, was desalted with Sephadex G 25 and mixed with CNBr-activated 
Sepharose (20 ml) in 50 ml of 0.15 M NaCl-0.10 M NaHCOs, pH 8.0. In order 
to protect the heparin binding site of the antithrombin molecule, heparin 
(150 mg) was also added. 
flask for 20 hours at O°C. 
The mixture was gently rotated in a round bottomed 
Excess CNBr-activated groups were blocked by the 
addition of 5 ml of 1.0 M ethanol-amine solution, pH 8.0 (13). The anti- 
thrombin III immobilized gel was sequentially washed with 0.17 M NaCl and 1.5 
M NaCl, collecting all washings. Quantitation of antithrombin III levels in 
the collected eluate revealed that 70% of the total antithrombin III was 
covalently bound to the gel. Affinity chromatography of both the albumin- 
heparin conjugate and heparin was performed as follows. A sample of albumin- 
heparin conjugate (100 mg in 10 ml 0.17 M NaCl-0.025 M Tris-HCl, pH 7.5) or 
heparin (5 mg in 5 ml 0.17 M NaCl-0.025 M Tris-HCl, pH 7.5) was applied to a 
column containing 20 ml of the prepared antithrombin III Sepharose gel, which 
was previously equilibrated with 0.17 M NaCl-0.025 M Tris-HCl, pH 7.5. Non- 
adsorbed materials (further indicated as low affinity (LA) heparin or albumin- 
heparin) were collected by washing the column with 2 column volumes of 0.17 M 
NaCl-0.025 M Tris-HCl, pH 7.5. The adsorbed materials (further indicated as 
high affinity (HA) heparin or albumin-heparin) were collected by washing the 
column with 2.0 M NaCl-0.025 M Tris-HCl, pH 7.5. The different fractions 
obtained were characterized by measuring the antithrombin and anti-factor Xa 
activities. 
RESULTS 
Preparation and Fractionation of Covalently Bound Albumin-Heparin Conjugates 
The method developed for coupling albumin and heparin with EDC was based 
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on the procedure described by Danishefsky for the coupling of aminoethyl 
agarose and heparin (14). Woodward's reagent K is also often used for the 
formation of amide bonds (e.g. 15). The coupling of albumin and heparin was 
also tried with this reagent, however, no detectable amounts of coupling pro- 
duct were formed although temperature, pH, reaction time and the weight ratio 
of heparin and Woodward's reagent K were varied. The yield obtained with the 
EDC coupling method was 35-40% based on the original amount of albumin used 
and this was not dependent on the scale used for the coupling reaction (50 mg- 
10 g albumin). Figure 1 shows the elution profile of the dialyzed reaction 
mixture using a DEAE-cellulose column. 
tracti33wmber 
FIG. 1 
Fractionation of albumin, heparin and the albumin-heparin conjugate on DEAE- 
cellulose. The arrows indicate: I, elution with 0.025 M Tris-HCl, pH 7.5; 
II, elution with 0.15 M NaCl-0.025 M Tris-HCl, pH 7.5; III, elution with 0.50 
M NaCl-0.025 M Tris-HCl, pH 7.5. Fractions of about 20 ml were collected. 
Figure 1 shows three separated albumin peaks. The first represents free 
albumin not bound on the column, the second represents free albumin bound on 
the column and the third represents albumin bound heparin. The fact that the 
third albumin peak doesn't coincide with the heparin peak demonstrates that 
free heparin was still present. Free heparin could be effectively removed by 
chromatography with Cibacron Blue Sepahrose. The elution profile is shown in 
Figure 2. 
From Figure 2 it appears that the fractions obtained by eluting the 
column with KSCN, contained albumin as well as heparin. It may be concluded 
that albumin coupling with heparin has occurred, free heparin doesn't interact 
with Cibacron Blue Sepharose, and heparin doesn't bind to albumin at physio- 
logical pH (5). 
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Rechromatography of the freeze dried albumin-heparin conjugate obtained 
on DEAE-cellulose and Cibacron Blue Sepharose showed that the preparation 
still contained about 5% free albumin, and no free heparin could be detected. 
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FIG 2 
Fractionation of heparin and albumin-heparin conjugate on Cibacron Blue 
Sepharose. The arrows indicate: I, elution with 0.17 M NaCl-0.025 M Tris- 
HCl, pH 7.5; II, elution of the column with 0.17 M NaCl-0.25 M KSCN-0.025 M 
Tris-HCl, pH 7.5. Fractions of 20 ml were collected. 
Characterization of the Albumin-Heparin Conjugates 
The weight % of heparin in the conjugates obtained using identical pro- 
cedures, varied between 10 and 12% as measured by the 2 calorimetric methods 
for the determination of heparin as previously described. Non systematic 
differences in the weight % of heparin up to 0.5% were observed when the 
results obtained with both methods were compared. When the coupling procedure 
was performed with a higher ratio of heparin to albumin, purified conjugates 
contained only a slightly higher weight % of heparin. Representative data 
are given in Table 1. 
TABLE 1 
Percentage of Heparin Present in the Albumin-Heparin Conjugates 
Prepared by Using Different Heparin Albumin Ratios. 
grams 
heparin 
used 
grams 
albumin 
used 
ratio 
heparinl l?C 
weight % of yield (albumin 
heparin in used for coupling/ 
albumin used conjugate albumin present 
in conjugate) 
0.15* 0.50* 0.3 50 10.2 52% 
0.50 0.50 1.0 50 13.5 56% 
1.50 0.50 3.0 50 15.6 61% 
*Standard concentration of reactants. 
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The elution patterns of the albumin-heparin conjugate and a mixture of 
albumin and heparin on Sephacryl S-300 are shown in Figure 3. 
The elution volume of the conjugate on Sephacryl S-300 (exclusion limit 
1 x 10s D for globular proteins) is smaller than the elution volume of both 
heparin and albumin. The fact that the elution profiles coincide shows that 
the coupling reaction was successful and that the albumin-heparin conjugate 
is stable at physiological pH. From the results shown in Figure 3 it can be 
concluded that the molecular weight distribution of the conjugate is rather 
broad. 
The biological activity of the albumin-heparin conjugates was compared 
with the activity of native heparin. Antithrombin activity (Fig. 4), anti- 
Factor Xa activity (Fig. 5) and activity against activated coagulation 
factors of the intrinsic pathway (APTT test, Fig. 6) were measured. 
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FIG. 3 
Gel filtration of the 
albumin-heparin conju- 
gate and of a mixture 
of albumin and heparin. 
3a. Conjugate on 
Sephacryl S-300. 
3b. A mixture of albu- 
min and heparin on 
Sephacryl S-300. 
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FIG. 4 
Thrombin clotting times as a 
function of the heparin [bound 
(A) or unbound(o)]concentration. 
FIG. 5 
Factor Xa inhibition as a function of 
the amount of heparin [bound (A) or 
unbound (0)] added in the presence of 
antithrombin. 
FIG. 6 
APTT as a function of the 
heparin [bound (A) or 
unbound (o)] concentration. 
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The results show that heparin bound to albumin still possesses a substantial 
heparin activity. Heparin in the albumin-heparin conjugate is more active 
than unbound heparin when tested with thrombin (ratio 1.25). An activity 
ratio of 0.5 was measured using a test for Factor Xa inhibition and the APTT 
test. 
Heparin and the albumin-heparin conjugates were fractionated with immo- 
bilized antithrombin III to yield portions with low affinity (LA) and high 
affinity (HA) for antithrombin III. Figure 7 shows the elution profile of 
the albumin-heparin conjugate on antithrombin III Sepharose. The LA and HA 
albumin-heparin conjugates obtained as well as LA and HA heparin were char- 
acterized by determining the antithrombin activity and the anti-Factor Xa 
activity (Fig. 8). 
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FIG. 7 
Elution profile of albumin- 
heparin conjugate on anti- 
thrombin III Sepharose. 
Arrows indicate: 1,elution 
with 0.17 M NaCl-0.025 M 
Tris-HCl, pH 7.5; II, 
elution with 2.0 M NaCl- 
0.025 M Tris-HCl, pH 7.5. 
Fractions of 5 ml were 
collected. 
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Anticoagulant activities of LA and HA albumin-heparin conjugates and LA and 
HA heparins. aa. Thrombin times of plasma in the presence of conjugate; 
8b. Thrombin times in the presence of heparin; 8c. Factor-Xa inhibition in 
the presence of conjugate; ad. Factor-Xa inhibition in the presence of 
heparin. (0) unfractionated, (A) LA material, (0) HA material. 
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DISCUSSION 
The results presented here demonstrate that albumin-heparin conjugates 
can be reproducibly synthesized using EDC as a coupling agent. The conjugate 
contains about 40% of the albumin available for the reaction. EDC activates 
carboxyl groups which are present in heparin as well as in albumin (99 per 
molecule, (16)). The activated carboxyl groups react almost exclusively with 
amine groups of albumin. In principle a wide variety of coupling products 
like alb-hep, alb-alb, alb-alb-hep, hep-alb-hep can be expected. The results 
presented in Table I show that a variation of the ratio of albumin to heparin 
in the reaction mixture (0.3-3.0) only leads to small changes in the weight 
percentage of heparin in the conjugate while the yields were almost the same. 
This indicates that the carboxyl groups in heparin are more reactive than 
those in albumin, which might be due to more pronounced shielding of the 
carboxyl groups in albumin as compared to heparin. 
The elution profile of the unpurified albumin-heparin conjugate on DEAE- 
cellulose was measured by determining heparin concentrations and albumin con- 
centrations in the subsequent fractions. Figure 1 shows that after the 
elution of the column with 0.50 M NaCl, two main peaks were observed, which 
indicates that albumin-heparin as well as free heparin is present. Further 
purification was carried out with Cibacron Blue Sepharose. With this material 
free heparin could be effectively removed, indicating that the heparin moiety 
in the conjugate doesn't prohibit the binding of the albumin moiety onto 
Cibacron Blue Sepharose. 
The anticoagulant activity of the conjugate is different from that of 
heparin. As pointed out by Danishefsky et al. (17), modification of heparin 
carboxyl groups leads to a decreased anticoagulant activity. In the coupling 
reaction of albumin and heparin, heparin carboxyl groups are modified and 
consequently the heparin activity changed. As expected, the anti-Factor Xa 
activity (Fig. 5) and the activity measured with the APTT assay (Fig. 6) of 
the conjugate, based on the amount of heparin present in the conjugate, is 
lower (ratio0.5) than native heparin; but in contrast, the antithrombin 
activity (Fig. 4) is slightly higher than native heparin. This might be 
explained by the following. Thrombin inactivation by antithrombin III in the 
presence of heparin proceeds via a complex of antithrombin III and thrombin 
with heparin. Factor Xa inactivation, however, only requires binding of 
heparin with antithrombin III (18). To neutralize thrombin activity, heparin 
molecules must contain binding regions for both antithrombin III and thrombin. 
Heparin is heterogeneous and contains molecules which bind either antithrombin 
III or thrombin. Combination of such molecules in conjugates like hep-alb-hep 
can lead to increased rates of thrombin inactivation by providing a single 
molecule with both thrombin and antithrombin III binding sites. Another 
possibility is that albumin enhances the activity of conjugated heparin. 
Teien et al. (19) prepared heparin-dextran-albumin conjugates and claimed 
these to have the same activity as heparin in test systems such as APTT, 
Thrombotest and thrombin clotting times. These conjugates were not purified 
and a considerable amount of free heparin was present, which makes the inter- 
pretation of the results difficult. 
As expected, the amide linkage between albumin and heparin is stable. 
With gel filtration chromatography and rechromatography of purified conju- 
gates no free heparin was detected. However, rechromatography of purified 
conjugate with DEAE-cellulose showed that the conjugate still contained 5-10% 
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of free albumin. This is caused by the fact that free albumin is not removed 
quantitatively by eluting the DEAE-cellulose column with 0.15 M NaCl-0.025 M 
Tris-HCl, pH 7.5. Because no free heparin was detected in the conjugates 
obtained, the free albumin does not originate from decomposed conjugate. 
Affinity chromatography with antithrombin III Sepahrose provides heparin 
fractions with high antithrombin III affinity (and high anticoagulant activ- 
ity) and with low antithrombin III affinity (and low anticoagulant activity) 
(12,20,21). The albumin-heparin conjugates can be fractionated in a similar 
way into low affinity (LA) and high affinity (HA) conjugates (Fig. 7), which 
were compared with unfractionated conjugate by determining the respective 
antithrombin and anti-Factor Xa activities. Because the antithrombin III 
column used had a low heparin binding capacity, elution was performed step 
wise. The weight % of heparin for HA and LA conjugates was 14.1 and 9.5, 
respectively. The differences in these weight fractions can be explained by 
the following facts. The ratio of HA to LA increases with increasing average 
molecular weights of heparin (21). Therefore, the heparin components of HA 
conjugates may be of higher average molecular weight than the heparin com- 
ponents of LA conjugates. Consequently, the HA conjugate contains a higher 
weight % of heparin than either the LA and unfractionated conjugate. The 
observation that the heparin binding capacity of the antithrombin III column 
used for fractionation of the conjugate is slightly higher than for native 
heparin (3.0 mg and 2.8 mg, respectively) support these presumptions. 
Current investigations deal with the efficacy of adsorbed albumin-heparin 
conjugates for the prevention of surface thrombosis. 
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